Juno Therapeutics announced that the FDA has granted Breakthrough Therapy designation to JCAR015, a chimeric antigen receptor for the treatment of relapsed or refractory B-cell acute lymphoblastic leukemia.

RELATED: FDA Grants Orphan Drug Status to Investigational Acute Myeloid Leukemia Treatment

All three of Juno’s CAR T cell product candidates currently in clinical trials, including JCAR015, are based on chimeric antigen receptor technology that employs the body’s immune system to attack cancer cells. JCAR017 is being tested for relapsed/refractory CD19-positive pediatric leukemia. JCAR014 is being tested for refractory chronic lymphocytic leukemia, non-Hodgkin’s lymphoma and acute lymphoblastic leukemia.

For more information visit JunoTherapeutics.com.